Unichem Laboratories Ltd
Unichem Laboratories Ltd is involved in pharmaceuticals
 in Generics, APIs and Contract Manufacturing (CMO) areas.[1]
- Market Cap ₹ 3,333 Cr.
 - Current Price ₹ 473
 - High / Low ₹ 950 / 455
 - Stock P/E 24.5
 - Book Value ₹ 349
 - Dividend Yield 0.00 %
 - ROCE 7.49 %
 - ROE 6.67 %
 - Face Value ₹ 2.00
 
Pros
- Company is almost debt free.
 - Company has delivered good profit growth of 37.4% CAGR over last 5 years
 
Cons
- Company has a low return on equity of -1.02% over last 3 years.
 - Company has high debtors of 157 days.
 
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,044 | 1,091 | 1,221 | 576 | 666 | 968 | 904 | 1,124 | 943 | 1,072 | 1,442 | 1,736 | 1,730 | |
| 863 | 989 | 1,078 | 813 | 798 | 1,019 | 994 | 1,028 | 986 | 1,165 | 1,391 | 1,482 | 1,491 | |
| Operating Profit | 181 | 102 | 142 | -237 | -132 | -52 | -89 | 95 | -43 | -93 | 51 | 254 | 239 | 
| OPM % | 17% | 9% | 12% | -41% | -20% | -5% | -10% | 8% | -5% | -9% | 4% | 15% | 14% | 
| 84 | 20 | 19 | 366 | 2,737 | 94 | 98 | 47 | 42 | -71 | -27 | 45 | 40 | |
| Interest | 2 | 2 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 9 | 10 | 8 | 8 | 
| Depreciation | 43 | 38 | 35 | 39 | 45 | 62 | 71 | 76 | 83 | 106 | 105 | 108 | 112 | 
| Profit before tax | 220 | 82 | 124 | 87 | 2,556 | -20 | -64 | 66 | -87 | -279 | -92 | 183 | 159 | 
| Tax % | 20% | 21% | 19% | -19% | -0% | -144% | -12% | 18% | -36% | 7% | 0% | 11% | |
| 177 | 64 | 100 | 104 | 2,557 | 9 | -56 | 54 | -55 | -300 | -92 | 163 | 140 | |
| EPS in Rs | 19.52 | 7.09 | 11.06 | 11.43 | 363.48 | 1.25 | -8.00 | 7.68 | -7.87 | -42.57 | -13.09 | 23.15 | 19.83 | 
| Dividend Payout % | 41% | 28% | 18% | 26% | 1% | 320% | -50% | 52% | -51% | -9% | 0% | 0% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% | 
| 5 Years: | 14% | 
| 3 Years: | 23% | 
| TTM: | 16% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% | 
| 5 Years: | 37% | 
| 3 Years: | 70% | 
| TTM: | 5110% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% | 
| 5 Years: | 15% | 
| 3 Years: | 2% | 
| 1 Year: | -45% | 
| Return on Equity | |
|---|---|
| 10 Years: | 11% | 
| 5 Years: | -1% | 
| 3 Years: | -1% | 
| Last Year: | 7% | 
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 
| Reserves | 888 | 929 | 1,009 | 1,113 | 2,748 | 2,718 | 2,633 | 2,683 | 2,658 | 2,370 | 2,281 | 2,446 | 
| 1 | 0 | 8 | 1 | 0 | 0 | 17 | 1 | 132 | 108 | 70 | 123 | |
| 300 | 274 | 306 | 371 | 346 | 298 | 361 | 420 | 318 | 394 | 477 | 527 | |
| Total Liabilities | 1,207 | 1,222 | 1,342 | 1,503 | 3,108 | 3,030 | 3,025 | 3,119 | 3,122 | 2,886 | 2,842 | 3,109 | 
| 394 | 396 | 381 | 468 | 555 | 789 | 829 | 850 | 963 | 1,236 | 1,165 | 1,275 | |
| CWIP | 86 | 119 | 233 | 247 | 236 | 90 | 331 | 568 | 494 | 148 | 122 | 31 | 
| Investments | 120 | 153 | 111 | 89 | 979 | 1,042 | 668 | 520 | 390 | 41 | 44 | 46 | 
| 607 | 555 | 617 | 698 | 1,338 | 1,109 | 1,197 | 1,181 | 1,275 | 1,462 | 1,510 | 1,758 | |
| Total Assets | 1,207 | 1,222 | 1,342 | 1,503 | 3,108 | 3,030 | 3,025 | 3,119 | 3,122 | 2,886 | 2,842 | 3,109 | 
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87 | 88 | 117 | 141 | -66 | -251 | -42 | -33 | -158 | -117 | -42 | 72 | |
| 35 | -62 | -87 | -132 | 1,648 | -323 | -36 | -73 | 104 | 241 | 60 | -133 | |
| -98 | -47 | -39 | -9 | -930 | -45 | -21 | -45 | 96 | -62 | -48 | -5 | |
| Net Cash Flow | 24 | -21 | -9 | -0 | 653 | -619 | -98 | -150 | 42 | 62 | -30 | -65 | 
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 69 | 79 | 188 | 127 | 125 | 130 | 117 | 147 | 161 | 141 | 157 | 
| Inventory Days | 183 | 159 | 162 | 371 | 216 | 242 | 301 | 326 | 438 | 335 | 264 | 267 | 
| Days Payable | 149 | 122 | 153 | 334 | 220 | 170 | 199 | 159 | 150 | 170 | 132 | 120 | 
| Cash Conversion Cycle | 108 | 106 | 88 | 225 | 123 | 197 | 233 | 284 | 436 | 325 | 274 | 305 | 
| Working Capital Days | 101 | 95 | 98 | 233 | 190 | 222 | 215 | 208 | 271 | 254 | 199 | 202 | 
| ROCE % | 19% | 9% | 13% | -8% | 132% | -0% | -2% | 2% | -3% | -6% | -1% | 7% | 
Documents
Announcements
- 
        
          General Update
          
            28 Oct - Paid €16,753,873.41 fine (including interest) to European Commission on 28 Oct 2025 in Perindopril matter.
 - 
        
          Board Meeting Intimation for Unaudited Financial Results (Consolidated And Standalone) For The Second Quarter And Six Months Ended September 30, 2025.
          
            15 Oct - Board meeting Nov 11, 2025 to approve Q2 and H1 unaudited results ended Sep 30, 2025.
 - 
        
          3Rd Report On Re-Lodgement Of Transfer Requests Of Physical Shares For The Month Ended 30Th September 2025.
          
            11 Oct - 3rd RTA report dated 10-Oct-2025 on re-lodgement of physical share transfer requests for month ended 30-Sep-2025.
 - 
        
          Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
          
            7 Oct - Compliance certificate under Reg. 74(5) of SEBI (Depositories and Participants) Regulation, 2018, for the quarter ended September 30, 2025
 - 
        
          Intimation Of Change In Email Address Of MUFG Intime India Private Limited, Registrar And Share Transfer Agent ('MUFG')
          
            6 Oct - MUFG Intime registrar email changed to Investor.helpdesk@in.mpms.mufg.com effective Oct 1, 2025.
 
Annual reports
- 
    
      Financial Year 2025
      from bse
 - 
    
      Financial Year 2024
      from bse
 - 
    
      Financial Year 2023
      from bse
 - 
    
      Financial Year 2022
      from bse
 - 
    
      Financial Year 2021
      from bse
 - 
    
      Financial Year 2020
      from bse
 - 
    
      Financial Year 2019
      from bse
 - 
    
      Financial Year 2018
      from bse
 - 
    
      Financial Year 2017
      from bse
 - 
    
      Financial Year 2016
      from bse
 - 
    
      Financial Year 2015
      from bse
 - 
    
      Financial Year 2014
      from bse
 - 
    
      Financial Year 2013
      from bse
 - 
    
      Financial Year 2012
      from nse
 - 
    
      Financial Year 2012
      from bse
 
Concalls
- 
      Jun 2017TranscriptNotesPPT
 - 
      Feb 2017Transcript PPT
 - 
      Nov 2016Transcript PPT
 - 
      Aug 2016Transcript PPT
 - 
      Jun 2016Transcript PPT
 - 
      Feb 2016Transcript PPT
 
Therapeutic Areas
The company manufactures and markets APIs and pharmaceutical formulations as branded & non-branded generics. The company’s products cater to diverse therapeutic areas such as cardiology, gas, diabetology, gastroenterology psychiatry, neurology, antibacterial, anti-infective, and pain management. [1]